TG
CLDX icon

TCW Group’s Celldex Therapeutics CLDX Stock Holding History

TCW Group’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-4,483
Closed -$2.38M – 762
2013
Q3 		$2.38M Sell
4,483
-14,890
-77% -$5.11M 0.01% 635
2013
Q2 		$4.54M Buy
+19,373
New +$3.81M 0.02% 494

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
SCA
SAC Capital Advisors Stamford, Connecticut $19.3B AUM 31.93% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

TCW Group's CLDX Position: Q4 2013 in Review

TCW Group sold out of Celldex Therapeutics (CLDX) in Q4 2013, closing a stake of 4,483 shares — an estimated $2.38M sold.

TCW Group first reported a position in CLDX in Q2 2013 and held it in 2 quarters. The position peaked at $4.54M in Q2 2013. 162 funds tracked by Wall St. Rank hold CLDX as of Q4 2013.

  • TCW Group reported no remaining Celldex Therapeutics position as of Q4 2013 after selling out during the quarter.
  • TCW Group sold 4,483 Celldex Therapeutics shares in Q4 2013, an estimated $2.38M.
  • TCW Group first reported a position in Celldex Therapeutics in Q2 2013 and held it in 2 quarters.
  • TCW Group's Celldex Therapeutics position peaked at $4.54M in Q2 2013.
  • 162 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2013.

Based on TCW Group's 13F filing for Q4 2013, filed 14 Feb 2014.